Bold claim: a protein linked to neurodegenerative diseases like dementia and ALS also governs DNA mismatch repair, a central process that preserves genetic information and cell health. New Houston Methodist research suggests this protein, TDP43, is a key regulator of mismatch repair genes. When TDP43 is either missing or overproduced, these repair genes become overactive, harming neurons and destabilizing the genome, which could contribute to cancer.
Lead investigator Muralidhar L. Hegde, Ph.D., a professor of neurosurgery at the Houston Methodist Research Institute's Center for Neuroregeneration, explains that DNA repair is a foundational biological process. The findings position TDP43 not merely as an RNA-binding protein involved in splicing, but as a crucial regulator of the mismatch repair system. This has significant implications for diseases such as ALS and frontotemporal dementia (FTD), where TDP43 dysfunction is common.
The study also uncovers a link between TDP43 and cancer. Analysis of large cancer datasets shows that high levels of the protein correlate with increased mutation loads. This indicates that TDP43 biology spans beyond neurodegeneration and touches on cancer biology as well, placing it at the intersection of two major disease domains of our time.
Impact and next steps: the researchers demonstrated that dampening overactive DNA repair in laboratory models partially reverses damage caused by TDP43 problems. Hegde notes that controlling DNA mismatch repair could become a therapeutic strategy for relevant conditions.
Contributors include: Vincent Provasek, Suganya Rangaswamy, Manohar Kodavati, Joy Mitra, Vikas Malojirao, Velmarini Vasquez, Gavin Britz, and Sankar Mitra from Houston Methodist; Albino Bacolla and John Tainer from MD Anderson Cancer Center; Issa Yusuf and Zuoshang Xu from the University of Massachusetts; Guo-Min Li from UT Southwestern Medical Center; and Ralph Garruto from Binghamton University.
Funding and support came mainly from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIH), with additional backing from the Sherman Foundation Parkinson's Disease Research Challenge Fund and internal Houston Methodist Research Institute funds.
Note: This summary references the Journal of Nucleic Acids Research and related institutional recognitions. For medical guidance or decisions, consult a professional. This rewrite aims to preserve core information while clarifying complex ideas for readers new to the topic. Would you like this rewritten piece tailored for a general audience, researchers, or a healthcare-news briefing with more lay explanations and practical takeaways?
